The new semaglutide drug approved in the UK: what's actually changed

You've read about a new semaglutide pill, here's what was actually approved and when

Picture this: you searched the news a few months ago, saw something about a semaglutide tablet, bookmarked it, and are now trying to work out whether it's real, available, and relevant to you. It is, but the detail matters.

Semaglutide is the medicine at the heart of Wegovy, a GLP-1 receptor agonist that works by mimicking a gut hormone involved in appetite regulation and the sense of fullness after eating. Until 2026 it was only available by weekly injection. On 11 June 2026, the MHRA approved Wegovy tablets as the first oral GLP-1 medicine licensed for weight management in the UK, making the UK the first country in Europe to grant that authorisation.

The tablet contains semaglutide combined with an absorption enhancer called SNAC, which allows the medicine to cross from the gut into the bloodstream when taken under tightly specific conditions. That detail matters practically: the tablet must be swallowed whole, first thing in the morning, with no more than a small amount of plain water, at least 30 minutes before any food, coffee, or other oral medicines. Deviate from that routine and absorption falls. The full semaglutide drug profile covers the mechanism in more depth if you want to understand how both the injection and tablet versions act on the body.

Separately, on 14 April 2026, the MHRA also approved a dedicated single-dose 7.2mg Wegovy pen (one pre-set weekly injection) for adults with a BMI of 30 or above. That approval extended the injection's ceiling and brought its average results closer to those seen with tirzepatide at higher doses.

What the trial evidence says about the new oral form

A question our prescribers hear most weeks is some version of: "Is the tablet as effective as the injection?" The honest answer is: close, but not identical, and the comparison depends heavily on adherence.

The phase-3 OASIS 4 trial enrolled 307 adults living with obesity or overweight plus at least one weight-related condition, without type 2 diabetes, over 64 weeks. Participants taking the 25mg tablet alongside lifestyle changes lost an average of around 13.6% of their body weight, compared with around 2.4% on placebo. Among those who stayed fully adherent to the dosing routine throughout, average loss reached approximately 16.6%. Those two figures are both real; which one you quote depends on what question you're answering. The higher figure has real meaning, but it belongs in the context of consistent adherence, that is how Wegovy works best, in either form.

The STEP 1 trial, published in the New England Journal of Medicine, reported an average of around 15% body-weight reduction over 68 weeks for the 2.4mg weekly injection. So the injection at its established maintenance dose still sits above the tablet's trial average, though the tablet's adherent-group figure narrows that gap considerably.

Side effects across both forms follow a similar pattern: nausea, loose stools, constipation and reflux are most common, tending to peak when doses are increased and settle within days to a couple of weeks. Gastrointestinal effects were reported in 74% of participants on the tablet in OASIS 4, compared with 42% on placebo, notably higher than the injection, likely reflecting the oral route. Starting low and titrating slowly is the practical answer to most of this. The dosing schedule moves from 1.5mg through 4mg and 9mg to the 25mg maintenance level, with at least a month between each step.

Who these new semaglutide approvals are licensed for

Both the Wegovy injection and the Wegovy tablet are licensed for adults with a BMI of 30 or above, or 27 to 29.9 with at least one weight-related condition such as high blood pressure, high cholesterol, or obstructive sleep apnoea. Lower BMI thresholds may apply for some ethnic backgrounds under UK guidance, your prescriber will apply the correct threshold for your circumstances.

Neither form is recommended during pregnancy, while breastfeeding, or when trying to conceive. Treatment is not licensed for under-18s. People with a history of certain thyroid conditions, pancreatitis or specific gastrointestinal disorders will need to discuss those with a prescriber before starting.

The MHRA's approval of the tablet is for weight management only. Rybelsus (also an oral semaglutide tablet) is a separate product licensed for type 2 diabetes at different strengths (3mg, 7mg, 14mg). Those strengths have no role in the Wegovy tablet's dosing schedule and should not be confused with it. If you've seen references to different semaglutide labels and brand names, that distinction explains most of the confusion.

On the NHS, access to Wegovy injection runs through specialist weight management services under NICE guidance (TA875), where waiting lists can be long. The Wegovy tablet has no NICE appraisal yet and is currently available through private prescription only. For people who don't meet NHS thresholds or prefer not to wait, a regulated private pharmacy is the practical route. You can check the GPhC register entry for our pharmacy to verify we are registered, that check takes about 30 seconds and is worth doing for any online pharmacy you're considering. For a fuller picture of how private treatment is priced and what a single transparent fee typically covers, the Wegovy cost comparison page lays it out plainly.

What 'new' actually means for someone deciding whether to start

The practical significance of these approvals varies by person. For someone who dislikes injections or travels frequently, the tablet's room-temperature storage and needle-free administration removes a real barrier. For someone who struggles with morning routines or takes other medicines first thing, the oral dosing window may be genuinely inconvenient. Neither form is automatically better, the right choice depends on your circumstances, your history, and what your prescriber knows about both.

The latest Wegovy developments page has more on how the 7.2mg injection pen and the oral tablet fit into the wider treatment picture. If you want to compare the two semaglutide forms side by side against each other and against tirzepatide, the semaglutide overview brings the evidence together. The MHRA's published approval announcement for the 7.2mg pen is also worth reading if you want the regulator's own words on what the data showed.

If you're weighing up whether either of these options suits you, a free consultation with a GPhC-registered prescriber is the sensible next step. Start your free consultation at our treatment page and a real clinician will review your case the same day.